Clinical trials
Metastatic clinical trials
Below are recruiting metastatic clinical trials, each written for real people, not researchers. We’re tracking 2,343 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07582315RecruitingPhase 3
BL-B01D1 for advanced biliary tract cancer after prior treatments
This study tests a new drug called BL-B01D1 against standard treatment options for patients with advanced biliary tract cancer (cancer of the bile ducts) that has stopped responding to platinum chemotherapy and immunotherapy. The drug is designed to target and destroy cancer cells more effectively.
Beijing, Beijing MunicipalityAges 18–75 - NCT07585266RecruitingPhase 3
New drug velzatinib versus imatinib for untreated GIST
This trial compares a newer cancer drug (velzatinib) with a standard treatment (imatinib) for gastrointestinal stromal tumors (GIST) that cannot be surgically removed or have spread. You would receive one of these two drugs to see which works better and is safer.
Scottsdale, ArizonaAges 18 years+ - NCT07583485Recruiting
Tucatinib combination therapy for advanced HER2-positive breast cancer
This study watches how well a three-drug combination (tucatinib, capecitabine, and trastuzumab) works for women with breast cancer that has spread to other parts of the body and has a protein called HER2. You'll be treated as you normally would be in a clinic, and researchers will track how you respond.
Avellino, AVAges 18 years+ - NCT07584499RecruitingPhase 1
New drug test for children with EGFR-positive solid tumors
This study tests a new cancer drug called Becotatug Vedotin in children ages 2–18 with certain types of solid tumors (cancers that form in organs or tissues) that have an EGFR protein. The drug is designed to find tumors with this protein and attack cancer cells while sparing healthy ones.
Guangzhou, GuangdongAges 2–18 - NCT07581821RecruitingPhase 2
Immunotherapy plus targeted drugs for advanced nasopharyngeal cancer
This trial tests a combination of three drugs (sintilimab, anlotinib, and chemotherapy) for nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this combination helps slow or shrink the cancer.
Zhuhai, GuangdongAges 18–65 - NCT07583654RecruitingPhase 1
Testing a New mRNA Cancer Treatment for Advanced Solid Tumors
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
Chengdu, SichuanAges 18–70 - NCT07572760Recruiting
Power Training for Men With Advanced Prostate Cancer
This study tests whether light-to-moderate strength training exercises can help men with advanced prostate cancer that has spread to bones or lymph nodes. The goal is to see if exercise improves physical strength and quality of life while you continue your cancer medications.
San Vicent del Raspeig, AlicanteAges 50 years+ - NCT06728852RecruitingPhase 2
Vorolanib for advanced lung cancer after other treatments
This trial tests a targeted therapy pill called Vorolanib for people with advanced non-small cell lung cancer who have already tried at least two other treatments. It aims to see if the drug can help shrink or control the cancer.
Guangzhou, GuangdongAges 18–70 - NCT06727630RecruitingPhase 1/Phase 2
A study of PRJ1-3024 for advanced or spreading melanoma
This trial tests a new drug called PRJ1-3024 for people with advanced melanoma that has not responded to standard treatment. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05668962RecruitingPhase 2
Study selpercatinib plus I-131 for RET thyroid cancer that cannot take iodine
This trial tests whether combining a targeted pill (selpercatinib) with a radioactive iodine dose (I-131) can shrink thyroid cancer that has spread and no longer responds to radioactive iodine. It is for RET fusion–positive (genetically driven) thyroid cancers where the cancer cannot reliably absorb iodine anymore.
Washington D.C., District of ColumbiaAges 12 years+ - NCT06636981RecruitingPhase 2
Combination therapy for advanced triple negative breast cancer
This trial tests a new combination of a vitamin A derivative (all-trans retinoic acid), an immunotherapy drug (toripalimab), and chemotherapy for people with advanced triple negative breast cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink or control the cancer better than current treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07563595Recruiting
Elacestrant for advanced ER+ HER2- breast cancer with ESR1 mutation
This trial tests elacestrant, a new hormone therapy drug, in women whose advanced or spread breast cancer has stopped responding to first-line hormone treatment. The drug is designed to work against a specific genetic change (ESR1 mutation) that can develop in these cancers.
Freiburg im BreisgauAges 18 years+ - NCT07563829RecruitingPhase 1
NPX372 immunotherapy for advanced solid tumors
This trial tests NPX372, a new type of immunotherapy designed to fight several types of advanced cancer that haven't responded to standard treatments. It works by combining two immune signals to help your body's immune system recognize and attack cancer cells.
La Jolla, CaliforniaAges 19 years+ - NCT07562438RecruitingPhase 2
Lutetium-177 Treatment for Advanced Prostate Cancer
This trial tests a radioactive medication (177Lu-P17-088) designed to target and treat prostate cancer that has spread to other parts of the body and stopped responding to hormone therapy. The medication is guided to cancer cells using a special imaging scan, potentially offering a new treatment option for men who have already tried other standard therapies.
Fuzhou, FujianAges 18–90 - NCT07564570Recruiting
Exercise Before Melanoma Immunotherapy Treatment
This study tests whether doing physical exercise right before receiving immunotherapy (two drugs called nivolumab and ipilimumab) helps treat advanced melanoma. The goal is to see if exercise boosts how well these cancer-fighting drugs work in your body.
Hamburg, Free and Hanseatic City of HamburgAges Any age - NCT07560748Recruiting
Prostate Cancer Registry and Research Study
This study collects medical information and tissue samples from men with prostate cancer to better understand the disease and improve future treatment. You'll provide consent and allow researchers to use your health data and biopsy samples for studies.
NijmegenAges 18 years+ - NCT07564232RecruitingPhase 1
LNK001 for Advanced Kidney Cancer After Prior Treatments
This Phase 1 trial tests a new cell therapy called LNK001 in patients with advanced clear-cell kidney cancer that has progressed despite prior immunotherapy and targeted drugs. The therapy is designed to recognize and attack cancer cells by targeting a protein called CAIX.
Houston, TexasAges 18 years+ - NCT07559864RecruitingPhase 2
Regorafenib plus Envafolimab for treatment-resistant gastrointestinal stromal tumors
This study tests a combination of two drugs (regorafenib and envafolimab) for gastrointestinal stromal tumors (a type of stomach/bowel cancer) that have stopped responding to standard treatments. The trial compares this combination to other doctor-selected treatments to see if it slows tumor growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06734533Recruiting
Anlotinib combo for HR+ breast cancer that has spread
This trial tests a combination treatment including anlotinib for women with hormone receptor-positive breast cancer that has spread to other parts of the body and has stopped responding to standard therapies. It is for those who have already tried a CDK4/6 inhibitor and endocrine therapy.
Changsha, HunanAges 18–75 - NCT06738459Recruiting
Matching lymph node tests in breast cancer
This study looks back at past MRI scans and lymph node biopsies or surgeries in people with breast cancer to better understand how cancer spreads to the lymph nodes. If you had these tests as part of your care, your data might help improve future treatment decisions.
VillachAges 18 years+ - NCT06349980RecruitingPhase 2
Study of three drugs for liver cancer not yet treated
This trial is testing a combination of three drugs (HLX10, HLX04, and HLX53) to find the best dose and see if they help people with advanced liver cancer who have not had systemic treatment before. The goal is to shrink tumors and improve survival.
ShanghaiAges 18 years+ - NCT07551440Recruiting
Finding treatment targets in advanced gastric cancer
This study looks for specific genetic or molecular markers in advanced gastric cancer that has spread to other parts of the body. The goal is to identify which treatments might work best for each patient's individual cancer.
Hong KongAges 18–80 - NCT07553572Recruiting
Smartphone app to track cancer symptoms during treatment
This study tests a smartphone application designed to help you monitor and manage side effects and symptoms while you're receiving chemotherapy or other systemic treatment for breast cancer, colorectal cancer, or lymphoma. The app may help your doctors catch problems early and support you throughout your treatment.
Boston, MassachusettsAges 18 years+ - NCT07554456RecruitingPhase 2/Phase 3
New Drug Combination for Advanced Esophageal Cancer
This trial tests a new drug called BL-B01D1 combined with an immune therapy (tislelizumab) and sometimes chemotherapy against standard chemotherapy for esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this new combination works better and is safer than current treatment.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic?
- Yes. Clin2 currently lists 2,343 recruiting metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.